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Objectives. This study examined the coronary vasoconstrictive
action of endogenous neuropeptide Y (NPY) during sympathetic
nerve stimulation and its modulation by the adenosine triphos-
phate (ATP)–sensitive potassium (KATP) channel in vivo.
Background. Exogenous NPY was characterized by its potent
vasoconstrictive effect. However, endogenous NPY has failed to
show any vasoconstrictive activity in vivo.
Methods. We studied 70 anesthetized dogs with vagotomy under
beta-adrenergic blockade. Ansae subclaviae stimulation and in-
tracoronary administration of the neurotransmitters (NPY and
norepinephrine) were done with or without alpha-adrenergic
blockade, NPY antagonist BIBP3226 or KATP channel acting
agents. We measured coronary vascular resistance (CVR) and the
neurotransmitter levels in systemic arteries and the great cardiac
vein, and the amount of overflow (venoarterial difference times
myocardial blood flow).
Results. During nerve stimulation, NPY levels correlated sig-
nificantly with CVR at the highest r value (r 5 0.850, p < 0.0001)
obtained for the venous level under alpha-blockade, but nor-
epinephrine showed no correlation. Treatment with BIBP3226
abolished the correlation between NPY level and CVR under
alpha-blockade. Without alpha-blockade, norepinephrine lev-
els correlated significantly with CVR; however, NPY showed no
correlation. The amount of NPY overflow during the stimulation
was nearly 1,000-fold lower than norepinephrine overflow. Exog-
enous NPY had a 100-fold more potent coronary vasoconstrictive
action than that of norepinephrine. The KATP channel antagonist
glibenclamide enhanced vasoconstriction of NPY, and the agonist
pinacidil suppressed it with a predominant effect in the subepi-
cardial region.
Conclusions. During sympathetic nerve stimulation, the vaso-
constrictive actions of NPY are masked by norepinephrine under
intact alpha-adrenoceptor conditions, manifest during alpha-
blockade and modulated by KATP channel activity.
(J Am Coll Cardiol 1997;29:1380–9)
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Neuropeptide Y (NPY), a 36-amino acid peptide, has a wide
distribution in both the central and the peripheral nervous
system (1), and cardiac perivascular sympathetic nerve fibers
contain high concentrations of NPY (2,3). In peripheral sym-
pathetic nerves, NPY is cosecreted with norepinephrine (4).
Exogenous NPY has been reported to have a variety of
functions, including regulation of coronary blood flow, cardiac
contractility and heart rate in anesthetized dogs (5–9). The
NPY-induced vasoconstriction is mainly mediated by way of
the Y1-receptor (10), which was antagonized by BIBP3226
(11,12). The effect of endogenous NPY on the coronary
circulation has not been determined. Otani et al. (13) con-
cluded that the quantity of released NPY during sympathetic
nerve stimulation was insufficient to elicit a coronary vasocon-
striction in vivo. The major aim of the present study was to
demonstrate endogenous NPY-related vasoconstriction during
sympathetic nerve stimulation in vivo by examining the quan-
titative relation between both the endogenous level and the
exogenous dose of NPY and changes in coronary vascular
resistance (CVR).
Reactive hyperemia has been shown to be modulated by
adenosine triphosphate (ATP)-sensitive potassium (KATP) chan-
nels during coronary occlusion (14). Recently, it has been dem-
onstrated that KATP channels modify the reactivity of coronary
vessels to exogenous norepinephrine (15,16). Therefore, the
second aim of this investigation was to determine the effects of
KATP channel activity on the relation between NPY and CVR.
Methods
General experimental conditions. This investigation con-
formed with the Guide for the Care and Use of Laboratory
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Animals published by the U.S. National Institutes of Health
(NIH publication no. 86-23, revised 1985). Seventy male and
female adult dogs (mean weight 14.3 6 5.8 kg) were anesthe-
tized with morphine hydrochloride and alpha-chloralose and
artificially ventilated as described previously (15). We isolated
the vagal nerves at the cervical level, severed them bilaterally
and blocked beta-adrenoceptor activity by intravenous admin-
istration of propranolol (2 mg/kg body weight) 15 min before
the initiation of the protocols to be described. We reinjected
propranolol (0.5 mg/kg) every hour to maintain the beta-
blockade to attenuate metabolic coronary regulation related to
heart rate. In 38 of 70 dogs, phenoxybenzamine (1 mg/kg
intravenously) was also administered to attenuate the vasocon-
strictive effects of norepinephrine by way of the alpha-
adrenoceptor.
In preliminary experiments, we investigated the effects of
competitive blockade of the beta-adrenoceptor with propran-
olol (2 mg/kg intravenously) and the alpha-adrenoceptor with
phenoxybenzamine (1 mg/kg, intravenously) by intravenous
administration of isoproterenol (0.01 to 10.0 mg/kg per min)
and intracoronary administration of phenylephrine (0.01 to
10.0 mg/kg per min), respectively. Propranolol elevated the
threshold of isoproterenol on chronotropic action from
0.03 mg/kg per min to 3.0 mg/kg per min; phenoxybenzamine
elevated the threshold of phenylephrine on CVR increase
from 0.3 mg/kg per min to .10.0 mg/kg per min, although this
dose caused an increase in aortic pressure .10%.
Specific surgical procedures and experimental protocols.
Protocol 1. Correlation between CVR and endogenous NPY and
norepinephrine. In 21 dogs, we performed sympathetic nerve
stimulation and analyzed the correlation between CVR and
the levels or the overflow of neurotransmitters (NPY and
norepinephrine) including data pairs at rest, 2 Hz and 20 Hz
under alpha- and beta-blockade (protocol 1A, 7 dogs), under
beta-blockade (protocol 1B, 7 dogs) and under alpha- and
beta-blockade plus NPY Y1–selective antagonist BIBP3226
(1 mg/kg, intravenously, Dr. Karl Thomae GmbH, Biberach,
Germany [protocol 1C, 7 dogs]).
Bilateral thoracotomy was performed in the fifth intercostal
space; the sternum was separated horizontally and the pericar-
dium incised. A 3F catheter was placed in the left atrium by
way of an appendage for the injection of nonradioactive
microspheres, and a 5F catheter was placed in the descending
aorta to obtain reference blood samples for the measurement
of myocardial blood flow. Two 7F catheters were placed in the
aortic arch by way of the left carotid artery and in the great
cardiac vein by way of the right jugular vein to obtain arterial
and venous blood samples, respectively, for the measurement
of neurotransmitter concentrations of NPY and norepineph-
rine. Aortic pressure was also recorded by means of the
catheter in the aorta.
The bilateral ansae subclaviae, which branch off from the
bilateral stellate ganglia, were isolated and ligated at the
proximal sites. Two coated stainless steel bipolar electrodes
were set on both sides of these nerves. The bilateral ansae
subclaviae were electrically stimulated for 2.5 min at 2 Hz (5 V,
1 ms), followed by 20 Hz for 2.5 min. Arterial and venous blood
samples were taken from the two 7F catheters during the final
1 min of each nerve stimulation period. In the same period,
microspheres containing solution were injected to measure the
coronary blood flow.
We calculated the correlation coefficient (r), determinant
coefficient (r2) and SD of the dependent variable from the
regression line corrected to the mean value of the dependent
variables (Syzx/y¯) for correlation analysis.
Protocol 2. Role of the KATP channel in endogenous NPY
stimulation of coronary vasoconstriction. In 14 dogs, we inves-
tigated the role of the KATP channel on coronary vasoconstric-
tion by endogenous NPY under alpha- and beta-blockade. The
experimental conditions were identical to those of protocol 1A
except for placement of an additional 3F catheter into the left
atrium. While either glibenclamide (0.6 mg/kg per min, Sigma
Chemical, seven dogs) or pinacidil (10 mg/kg per min,
Shionogi, Japan, seven dogs) was injected into the left atrium,
the nerve stimulation and the analyses were performed accord-
ing to protocol 1. Drug administration was started 2 min before
the electrical stimulation.
Protocol 3. Reactivity of coronary vessels to exogenous NPY
and norepinephrine. In 30 dogs, the changes in CVR induced
by intracoronary administration of NPY and norepinephrine
were examined. In the 10 dogs of protocol 3A, the dose
response of CVR to NPY (5 dogs) was compared with the dose
response to norepinephrine (5 dogs) under alpha- and beta-
adrenoceptor blockade. In the 20 dogs of protocol 3B, the dose
response of CVR to NPY (10 dogs) was compared with the
dose response to norepinephrine (10 dogs) under beta-
blockade.
Left-sided thoracotomy was performed at the fifth intercos-
tal space, and immediately after the ligation of the branch a
silicone tube bypass equipped with the flow probe of an
electromagnetic flowmeter (MFV2100, Nihon Kohden, Japan)
was set between the left subclavian artery and the proximal
branch of the left circumflex coronary artery. Before place-
ment of the bypass, heparin (3,000 to 5,000 U intravenously
followed by 1,000 to 2,000 U/h) was administered. Coronary
perfusion pressure was continuously recorded through the side
path of a bypass circuit. A 7F catheter was placed in the aortic
arch by way of the left carotid artery to measure the arterial
pressure. We confirmed reactive hyperemia after a 15-s occlu-
sion to be .200% of the basal flow 10 min before each
experiment.
Abbreviations and Acronyms
ANCOVA 5 analysis of covariance
ANOVA 5 analysis of variance
ATP 5 adenosine triphosphate
CVR 5 coronary vascular resistance
%CVR 5 percent changes in coronary vascular resistance
KATP channel 5 adenosine triphosphate–sensitive potassium channel
NPY 5 neuropeptide Y
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Either NPY (0.001, 0.003, 0.01, 0.03, 0.1, 0.3 mg/kg per min
[i.e., 0.00023 to 0.07 nmol/kg per min]; synthetic human NPY,
Peptide Institute, Japan) or norepinephrine (0.001, 0.003, 0.01,
0.03, 0.1, 0.3 mg/kg per min [i.e., 0.006 to 1.8 nmol/kg per min];
Waco Chemical, Japan) was administered through the side
path of the bypass circuit into the coronary artery and the dose
responsiveness of percent changes in coronary vascular resis-
tance (%CVR) to NPY or norepinephrine was analyzed. The
doses were increased in a stepwise manner every 1 min. In the
last stage of the experiment, Evans blue solution was admin-
istered through the bypass to identify the area perfused by the
bypass circuit.
We compared the dose response curves of %CVR to NPY
and norepinephrine under alpha-blockade (protocol 3A) and
under intact alpha-adrenoceptor (protocol 3B) by analysis of
covariance (ANCOVA).
Protocol 4. Role of KATP channel in exogenous NPY stimula-
tion of coronary vasoconstriction. In protocol 4A, we tested
whether either of three KATP channel acting agents could
modify the dose response to NPY under beta-blockade. Pro-
tocol 4A was performed in the 10 dogs in which the NPY dose
response (protocol 3B) had been evaluated. After 30 min of
protocol 3B, we confirmed recovery of heart rate and aortic
pressure to 90% to 110% of the baseline value of protocol 3B.
We then confirmed that the degree of the reactive hyperemia
was not different from that of the reactive hyperemia just
before protocol 3B (.200% of the basal flow). The dose
response to NPY was determined again under intracoronary
administration of a KATP channel antagonist (four dogs with
glibenclamide [30 mg/kg per min]) or agonist (three dogs with
pinacidil [0.5 mg/kg per min] and three dogs with nicorandil [10
mg/kg per min], Chugai Pharmaceutical, Japan). We compared
the dose-response curves of %CVR to NPY with and without
KATP channel-acting substances (the data for the control
curves came from protocol 3B) by ANCOVA.
In protocol 4B, we analyzed the dependence of exogenous
NPY and norepinephrine vasoconstriction on KATP channels
in the other five dogs. Four dose-response trials were per-
formed for each dog in the following order: 1) norepinephrine
dose response, 2) norepinephrine dose response with nicoran-
dil, 3) NPY dose response, and 4) NPY dose response with
nicorandil. Between each trial we left a 30-min intermission.
Before each trial, recovery of heart rate and aortic pressure to
90% to 110% of the original baseline value was confirmed.
Then the reactive hyperemia was confirmed to be .200% of
the basal flow. The substances tested above were administered
into the coronary artery as in protocol 4A under beta-
blockade. The degree of suppression by nicorandil in norepi-
nephrine dose response was estimated by the difference in
%CVR between the first and the second trials, and that in
NPY dose response was between the third and the fourth trials.
The effect of nicorandil suppression on NPY and norepineph-
rine was compared by ANCOVA.
Calculation of CVR. CVR (mm Hg/ml per min per 100 g)
was calculated as mean coronary perfusion pressure (or mean
aortic pressure) divided by coronary blood flow per 100 g of
myocardium measured with nonradioactive microspheres of
15-mm diameter by the X-ray fluorescence method (17) (pro-
tocols 1 and 2) or with an electromagnetic flowmeter set at the
subclavian-coronary bypass (protocols 3 and 4). The micro-
spheres were labeled with one of nine sets of stable heavy
elements (Ti, Br, Y, Zr, Nb, In, I, Ba, or Ce, Sekisui Plastic,
Japan) and were suspended in 0.05% sodium dodecyl sulfate at
a concentration of 2 3 106/ml. The microsphere solution (1 ml)
was gently infused over a period of 30 s to 1 min, and reference
blood was taken at a rate of 6 ml/min for 2 min beginning 10 s
before the microsphere infusion. After completion of the
experimental protocol, the heart was excised and the free wall
of the left ventricle taken out. The myocardium was cut into
two to three layers from the epicardium to the endocardium.
The X-ray fluorescence of each heavy element was measured
with a wave-length dispersive X-ray fluorescence spectrometer
(PW1480, Phillips, Holland). The blood flow was calculated
with the following equation:
Myocardial blood flow ~ml/min per 100g!
5 Sampling rate of reference blood 3 Tissue count
3 100/~Reference blood count 3 Tissue weight!.
Measurement of NPY and norepinephrine. Blood (;3 ml)
was collected in a chilled polystyrene tube, gently mixed with
20 mg of EDTA disodium, kept on ice for 5 min and then
centrifuged at 1,500 g for 20 min at 4°C. Plasma was pipetted
off and stored at 225°C until assay. NPY concentration was
estimated by radioimmunoassay. To remove plasma protein,
1 ml of acid ethanol was added to 0.5 ml of plasma. After
centrifugation, the supernatants were evaporated to dryness
(18). Radioimmunoassay was performed according to the
manufacturer’s protocol (Amersham International plc, UK)
using 125I-labeled human NPY (74 TBq/mmol, Amersham).
Synthetic human NPY was used as a standard. Anti-NPY
rabbit serum (Peptide Institute) was diluted to a final concen-
tration of 1:800,000. The antiserum revealed the specificity of
human NPY and porcine NPY to be 100%; human 1-9NPY,
human 24-36NPY, human pancreatic polypeptide and peptide
YY were present at ,0.1%. The detectable limit of NPY was
10 pmol/liter. The norepinephrine concentration was mea-
sured by fluorometric determination with diphenylethylenedia-
mine using high-performance liquid chromatography (19) after
removing plasma protein with perchloric acid. The detectable
limit of norepinephrine was 0.03 nmol/liter. The overflows of
NPY and norepinephrine in protocols 1 and 2 were calculated
with the following equation:
Overflow of NPY or norepinephrine ~mol/min per 100 g!
5 ~Concentration in the great cardiac vein
2 Concentration in the aorta) 3 Coronary blood flow.
Statistical analysis. All data obtained in this study are
expressed as mean value 6 SD. We applied an analysis of
variance (ANOVA) for repeated measures with the Scheffe´ F
test to determine the significance of the hemodynamic changes
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from the baseline during stimulation in all protocols, unpaired
t test for the mean values of CVR and concentrations of the
neurotransmitter between the two groups in protocol 2, and
correlation analysis between the neurotransmitter and CVR in
protocols 1 and 2. Analysis of covariance (ANCOVA) was
performed in protocols 3, 4A and 4B to compare the dose
responsiveness of the coronary vasculature to neurotransmitter
administration. In all three protocols, the concentration of
neurotransmitter was used as covariate. In protocols 3 and 4A,
%CVR was used as the dependent variable and the degree of
suppression of %CVR was the dependent variable in protocol
4B. In protocols 3 and 4B two kinds of neurotransmitters
(NPY and norepinephrine) were used as the grouping variable,
and the presence of KATP-acting agents was used in protocol
4A. Differences were considered significant where p , 0.05.
Results
Correlation between CVR and endogenous NPY (protocol
1). Bilateral ansae subclaviae stimulation of 2 and 20 Hz
produced stepwise increases in CVR and in levels and over-
flows of the neurotransmitters (NPY and norepinephrine) in
protocols 1A and B (Table 1). The venous concentrations of
NPY (290.3 6 77.3 pmol/liter) and the amounts of NPY
overflow (7.38 6 2.61 pmol/min per 100 g) were ;1,000-fold
less than those of norepinephrine (148.3 6 113.0 nmol/liter
and 6.37 6 4.29 nmol/min per 100 g) during 20-Hz stimulation
under beta-blockade. In the presence of BIBP3226 (protocol
1C), however, nerve stimulation did not cause the significant
increase of CVR, whereas the stimulation increased levels and
overflows of the neurotransmitters. Nerve stimulation did not
significantly change the subepicardial/subendocardial CVR
ratio.
CVR correlated significantly with venous and arterial con-
centrations of NPY under alpha- and beta-blockade (protocol
1A) but not under beta-blockade (protocol 1B) (Table 2, Fig.
1). However, norepinephrine significantly correlated with
CVR under intact alpha-adrenoceptor (under beta-blockade)
but did not correlate under alpha- and beta-blockade. Under
alpha- and beta-blockade, the values of the correlation coeffi-
cient (r) were highest for the venous NPY levels (r 5 0.850)
among the three indexes (arterial concentration, venous con-
centration and overflow). However, the determinant coefficient
(r2) was relatively low (r2 5 0.723). In contrast, the venous
norepinephrine level correlated with CVR with lower correla-
tion and determinant coefficients (r 5 0.732, r2 5 0.536) under
beta-blockade than those of the NPY-CVR correlation under
alpha- and beta-blockade. The treatment of BIBP3226 abol-
ished the correlation between NPY levels and CVR under
alpha- and beta-blockade (protocol 1C, Fig. 1C). We also
evaluated the correlations of CVR in the subepicardial and
subendocardial regions with the indexes of the neurotransmit-
ter. There was no obvious difference between the two regions;
the r2 values were 0.753 and 0.685 for venous concentration of
NPY in the subepicardial and subendocardial regions under
alpha- and beta-blockade, respectively, and 0.454 and 0.476 for
venous norepinephrine under beta-blockade, respectively. The
values of %CVR also correlated with the degree of increase in
norepinephrine or NPY on stimulation, where the degree of
increase was defined by the difference between the value
during the stimulation and that at baseline. However, the r
values were always less than those of the absolute values (data
not shown). Logarithmic transformation did not improve the
correlation coefficients in any indexes.
Role of the KATP channel in endogenous NPY stimulation
of coronary vasoconstriction (protocol 2). Even in the pres-
ence of KATP channel modulators, ansae subclaviae stimula-
tion also increased CVR and levels and overflows of the
neurotransmitters in protocol 2 (Table 1). Glibenclamide
treatment caused a significantly larger increase of %CVR in
the subepicardial region during nerve stimulation than in the
subendocardial region, whereas pinacidil treatment resulted
the opposite effect at 20-Hz stimulation.
The mean value of CVR, including the data from the
baseline, at 2-Hz and 20-Hz stimulations in the glibenclamide
treatment group, was significantly higher than that in the
pinacidil treatment group (2.38 6 1.17 [21 points in seven
dogs] vs. 0.87 6 0.29 mm Hg/ml per min per 100 g [21 points
in seven dogs], p , 0.0001 unpaired t test). However, between
the two groups significant differences in mean venous NPY
levels (271.1 6 128.5 vs. 305.1 6 171.8 pmol/liter) or mean
venous norepinephrine levels (30.5 6 42.4 vs. 28.9 6 36.9
nmol/liter) were not observed (unpaired t test). Unlike proto-
col 1, there was no significant correlation between CVR and
neurotransmitters in protocol 2. For example, the r values
between CVR and venous NPY concentration with gliben-
clamide and pinacidil were 0.158 and 0.111, respectively (data
not shown).
Reactivity of coronary vessels to exogenous NPY (protocol
3). Intracoronary administration of exogenous NPY increased
CVR in a dose-dependent manner and revealed a more potent
vasoconstrictive action than the same molar concentration of
norepinephrine, both under alpha- and beta-blockade (proto-
col 3A, p , 0.001 ANCOVA) and under beta-blockade
(protocol 3B, p , 0.001 ANCOVA) (Fig. 2). The concentra-
tion of NPY that increased CVR by 20% was ;100-fold lower
than that of norepinephrine under beta-blockade. Intracoro-
nary administration of exogenous norepinephrine caused only
a negligible change under alpha- and beta-blockade (0.98 6
0.18 mm Hg/ml per min per 100 g at baseline, n 5 5) except for
the maximal dose (0.3 mg/kg per min), but it caused a
dose-dependent increase of CVR under beta-blockade (1.49 6
0.52 mm Hg/ml per min per 100 g at baseline, n 5 10)
(ANOVA). The dose responsiveness of %CVR to norepineph-
rine was significantly suppressed by alpha-blockade (p , 0.001,
ANCOVA) but that to NPY was not significantly suppressed
(p 5 0.55, ANCOVA). During administration, heart rate did
not change significantly, nor did perfusion pressure, except for
a slight increase of perfusion pressure at the maximal dose of
NPY in protocol 3B (93.5 6 18.6 to 100.0 6 16.7 mm Hg, n 5
10) and of norepinephrine in protocols 3A (84.4 6 14.8 to
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88.8 6 17.9 mm Hg, n 5 5) and B (105.1 6 25.4 to 113.5 6
24.2 mm Hg, n 5 10) (p , 0.05, ANOVA).
Role of KATP channel in exogenous NPY stimulation of
coronary vasoconstriction (protocol 4). As shown in Figure 3,
treatment with the KATP channel antagonist glibenclamide
significantly enhanced %CVR during NPY administration (p ,
0.001, ANCOVA), whereas the agonists pinacidil or nicorandil
produced a significant reduction (p , 0.001, ANCOVA)
under beta-blockade (protocol 4A). There was no significant
difference in the effects of pinacidil and nicorandil on NPY
dose response (n 5 3 and n 5 3, respectively). The degree
of suppression in vasoconstriction by nicorandil was directly
proportional to the concentration of NPY and norepineph-
rine. NPY was more sensitive to the effect of nicorandil than
norepinephrine (p , 0.001, ANCOVA); that is, 15% sup-
pression in CVR was obtained at ;0.01 nmol/kg per min for
Table 1. Hemodynamic Variables During Ansae Subclaviae Stimulation in Protocols 1 and 2
Protocol 1A Protocol 1B Protocol 1C Protocol 2
Alpha- and Beta-
Blockade
(7 dogs)
Beta-
Blockade
(7 dogs)
Alpha- and Beta-Blockade
Plus BIBP3226
(7 dogs)
Alpha- and Beta-Blockade
Plus Glibenclamide
(7 dogs)
Alpha- and Beta-Blockade
Plus Pinacidil
(7 dogs)
Heart rate (beats/min)
Baseline 101.3 6 34.1 105.7 6 16.4 110.3 6 11.7 101.4 6 21.5 111.2 6 21.0
2 Hz 108.5 6 26.3 109.6 6 16.1 111.1 6 18.5 100.4 6 20.4 115.5 6 20.0
20 Hz 117.9 6 23.6*† 118.7 6 22.0*† 141.1 6 24.5*† 101.9 6 22.9 122.2 6 24.9*
Mean aortic pressure (mm Hg)
Baseline 70.1 6 24.9 109.4 6 19.1 77.0 6 12.5 85.7 6 14.2 61.6 6 21.4
2 Hz 78.9 6 30.0 113.6 6 16.4 81.7 6 8.1 99.9 6 13.5* 63.4 6 24.7
20 Hz 92.8 6 32.7*† 122.9 6 16.6*† 90.0 6 14.5 109.1 6 16.0* 71.3 6 27.8*†
Coronary blood flow (ml/min per 100 g)
Baseline 54.7 6 18.2 61.3 6 8.0 89.7 6 49.5 51.5 6 14.8 83.8 6 26.9
2 Hz 59.8 6 22.0 54.9 6 8.7 69.2 6 31.5 46.3 6 22.5 76.6 6 28.2
20 Hz 54.5 6 20.0 53.5 6 11.6 116.0 6 29.1† 45.4 6 19.0 76.3 6 28.6
CVR (mm Hg/ml per min per 100 g)
Baseline 1.35 6 0.55 1.80 6 0.30 1.08 6 0.53 1.75 6 0.47 0.78 6 0.31
2 Hz 1.53 6 1.04 2.10 6 0.35 1.35 6 0.44 2.58 6 1.31 0.87 6 0.29
20 Hz 1.96 6 1.13* 2.40 6 0.64* 0.81 6 0.19† 2.82 6 1.37* 0.96 6 0.27*
CVR ratio (subepi/subendo)
Baseline 1.45 6 0.69 1.38 6 0.31 1.33 6 0.70 1.39 6 0.19 1.21 6 0.08
2 Hz 1.36 6 0.52 1.28 6 0.22 1.23 6 0.39 1.73 6 0.31 1.29 6 0.20
20 Hz 1.31 6 0.38 1.31 6 0.15 1.33 6 0.51 1.99 6 0.56* 1.12 6 0.09
Arterial NPY (pmol/liter)
Baseline 161.1 6 92.9 144.1 6 59.9 302.7 6 108.2 219.3 6 73.1 285.3 6 161.3
2 Hz 172.6 6 98.7 137.4 6 59.0 330.7 6 127.8 208.6 6 109.6 282.6 6 146.2
20 Hz 203.6 6 138.0 155.6 6 58.3 377.1 6 146.6 228.9 6 102.0 298.9 6 181.4
Venous NPY (pmol/liter)
Baseline 159.7 6 106.8 156.9 6 66.3 221.6 6 113.8 201.7 6 80.6 258.1 6 161.9
2 Hz 224.0 6 134.7 169.6 6 52.6 272.1 6 134.0 224.7 6 83.8 281.3 6 160.1
20 Hz 369.6 6 227.1*† 290.3 6 77.3*† 492.4 6 166.6*† 386.9 6 133.4*† 375.9 6 193.4*†
NPY overflow (pmol/min per 100 g)
Baseline 20.39 6 4.28 0.74 6 1.81 26.15 6 3.43 21.08 6 1.65 22.46 6 3.08
2 Hz 2.80 6 4.17 1.86 6 1.66 23.97 6 5.24 20.42 6 2.91 20.14 6 2.95
20 Hz 7.53 6 4.11* 7.38 6 2.61*† 14.30 6 11.88*† 7.43 6 7.93*† 7.01 6 8.42*†
Arterial NE (nmol/liter)
Baseline 4.5 6 5.4 1.1 6 0.5 2.4 6 2.6 3.1 6 2.3 3.9 6 2.7
2 Hz 5.3 6 5.2 1.7 6 0.8 4.0 6 2.2 4.8 6 3.6 4.8 6 2.4
20 Hz 12.0 6 6.9*† 12.2 6 5.6*† 18.5 6 10.3*† 10.8 6 3.8*† 17.3 6 14.4*†
Venous NE (nmol/liter)
Baseline 4.4 6 9.3 0.9 6 0.4 0.9 6 0.6 2.5 6 1.9 3.8 6 2.1
2 Hz 23.4 6 24.3 7.6 6 4.1 28.9 6 12.7 9.5 6 2.0 11.1 6 4.1
20 Hz 100.7 6 58.8*† 148.3 6 113.0*† 200.3 6 134.7*† 79.4 6 41.9*† 71.9 6 35.6*†
NE overflow (nmol/min per 100 g)
Baseline 20.04 6 0.29 20.02 6 0.03 20.10 6 0.14 20.03 6 0.04 0.02 6 0.26
2 Hz 0.95 6 0.99 0.31 6 0.22 1.88 6 1.40 0.19 6 0.13 0.50 6 0.39
20 Hz 4.74 6 3.02*† 6.37 6 4.29*† 19.61 6 14.71*† 3.34 6 2.51*† 3.78 6 1.55*†
*p , 0.05 versus baseline value. †p , 0.05 versus value at 2 Hz (by analysis of variance). Data are expressed as mean value 6 SD. See Methods for definitions of
protocols 1 and 2. CVR 5 coronary vascular resistance; NE 5 norepinephrine; NPY 5 neuropeptide Y; subendo 5 subendocardium; subepi 5 subepicardium.
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NPY and at an ;100 times higher dose (1.0 nmol/kg per
min) for norepinephrine (protocol 4B, Fig. 4).
Discussion
New observations from this study. We have demonstrated
that during sympathetic nerve stimulation the vasoconstrictive
actions of NPY are masked by norepinephrine under intact
alpha-adrenoceptor conditions and become manifest during
alpha-blockade. The actions of both exogenous and endoge-
nous NPY on the reactivity of coronary vessels were modulated
by KATP channel activity.
Coronary vasoconstrictive action of endogenous NPY in
vivo. We quantitatively evaluated the vasoconstrictive effect of
both endogenous and exogenous NPY on coronary vessels in
vivo. In the presence of alpha-blockade, the endogenous NPY
level correlated significantly with CVR (r2 5 0.723) during
nerve stimulation (protocol 1A). It was NPY, not norepineph-
rine, that determined CVR at this condition, because 1) the
norepinephrine level did not correlate with CVR whereas NPY
did correlate in protocol 1A, 2) NPY Y1-antagonist BIBP3226
blocked the nerve stimulation–induced coronary vasoconstric-
tion and abolished the significant correlation between NPY
levels and CVR in protocol 1C, 3) alpha-blockade by phenoxy-
benzamine attenuated the effect of phenylephrine by .30-fold
(see Methods) and almost abolished the effect of exogenous
norepinephrine in protocol 3A, and 4) exogenous NPY main-
tained a potent vasoconstrictive action despite the presence of
alpha-blockade (protocol 3). Macho et al. (20) also reported
that phentolamine did not modify the coronary vasoconstric-
tive effect of NPY.
Under intact alpha-adrenoceptor, however, endogenous
NPY levels did not correlate with CVR, whereas norepineph-
rine levels showed good correlation (protocol 1B). This differ-
ence may be due to the low level of release or the low potency
of NPY compared with norepinephrine during nerve stimula-
tion. The former possibility could be explained by the results
obtained during ansae subclaviae stimulation where NPY
overflow was ;1,000-fold lower than norepinephrine overflow
in protocol 1, assuming the overflow to be an index of the level
of release. NPY occurred only in large, dense core vesicles, in
which the molar ratio of NPY to norepinephrine was ;1:200
(4,21,22). To investigate the latter possibility, we examined the
vasoconstrictive effect of NPY and norepinephrine indepen-
dently in protocol 3, where NPY had an ;100-fold greater
effect than norepinephrine. This value was comparable to the
results obtained in the isolated perfused dog heart (20).
The rough correlation between norepinephrine levels and
CVR (r2 5 0.536) under intact alpha-adrenoceptor indicated
that norepinephrine can account for only 54% of the variation
in CVR during the stimulation, which is less than that of NPY
under alpha-blockade. NPY probably contributes to some of
the residual 46% of variation. Thus, the vasoconstrictive
actions of endogenous NPY may be masked by norepinephrine
under intact alpha-adrenoceptor and is manifest only under
alpha-blockade. Under intact alpha-adrenoceptor, Otani et al.
(13) deduced that the quantity of released NPY during sym-
pathetic nerve stimulation was insufficient to elicit a coronary
vasoconstriction based on their indirect observations that 1)
after cessation of sympathetic nerve stimulation, CVR re-
turned rapidly to its control value, 2) coronary constriction by
exogenous NPY was sustained for 48 min, 3) intense anteced-
ent sympathetic stimulation did not alter the coronary vascular
responses to subsequent norepinephrine infusions, and 4) the
modulation of the vagal effect on heart rate induced by
sympathetic nerve stimulation persisted for ;1 h. In the
present study, however, we directly demonstrated NPY-
induced coronary vasoconstriction by showing a quantitative
correlation between NPY level and CVR under alpha-
blockade without NPY antagonist (protocol 1A) and lack of
correlation with NPY antagonist (protocol 1C). This vasocon-
strictive action was masked by the effects of norepinephrine
under intact alpha-adrenoceptor (protocol 1B).
CVR had correlated better with the venous concentration
of NPY and norepinephrine than with the overflow of these
transmitters. This finding suggested that the regulation of NPY
and norepinephrine levels coupled to adrenergic receptors
relies on the local venous concentrations rather than on the
amount of overflow. The local concentrations of NPY and
norepinephrine are determined by the quantity of release, the
rate of degradation, reuptake and washout. Our present find-
ings suggest that the rate of washout, or the flow rate in the
Table 2. Correlation Between Coronary Vascular Resistance and
the Neurotransmitters (neuropeptide Y and norepinephrine) in
Protocol 1
Correlation (vs. CVR)
r Value r2 Value p Value Syzx/y¯
Alpha- and Beta-Blockade (protocol 1A [21 points in 7 dogs])
Arterial NPY 0.680 0.462 0.0007 0.436
Venous NPY 0.850 0.723 0.0001 0.313
NPY overflow 0.285 0.081 NS 0.570
Arterial NE 20.166 0.027 NS 0.587
Venous NE 20.030 0.001 NS 0.594
NE overflow 0.090 0.008 NS 0.593
Beta-Blockade (protocol 1B [21 points in 7 dogs])
Arterial NPY 20.217 0.047 NS 0.238
Venous NPY 0.053 0.003 NS 0.243
NPY overflow 0.112 0.013 NS 0.242
Arterial NE 0.579 0.335 0.006 0.199
Venous NE 0.732 0.536 0.0002 0.166
NE overflow 0.674 0.454 0.0008 0.180
Alpha- and Beta-Blockade Plus BIBP3226 (protocol 1C [21 points in 7 dogs])
Arterial NPY 0.268 0.072 NS 0.416
Venous NPY 20.077 0.006 NS 0.431
NPY overflow 20.282 0.080 NS 0.414
Arterial NE 20.169 0.028 NS 0.426
Venous NE 20.276 0.067 NS 0.415
NE overflow 20.351 0.123 NS 0.405
NS 5 not significant (p value . 0.05); Syzx/y¯ 5 residual error normalized to
the mean; other abbreviations as in Table 1.
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tissue, modifies the local concentrations of NPY and norepi-
nephrine and thereby CVR. Released NPY was oxidized or
degraded into fragments (23). Piedimonte et al. (24) reported
that neutral endopeptidase inhibition, which probably reduced
degradation of bradykinin, potentiated sensory nerve–induced
coronary vasodilation. However, nothing is known about mod-
ification of NPY-induced coronary vasoconstriction by a spe-
cific peptidase. Reuptake of NPY by nerve terminals is also
unlikely.
The role of KATP channel in the modulation of CVR. The
relatively rough correlation between NPY levels and CVR
(r2 5 0.723) indicated that NPY can account for only 72% of
the variation in CVR during sympathetic nerve stimulation.
Other mechanisms may play additional modulatory roles for
CVR. The present results in protocols 2 and 4 indicate that the
KATP channel modulates CVR by changing the reactivity of
coronary vessels to NPY. A KATP channel antagonist enhanced
CVR and agonists attenuated CVR during administration of
exogenous NPY (protocol 4), and these substances modified
CVR without changing overflow or local levels of NPY or
Figure 1. Correlation of venous levels of neuropeptide Y (NPY, left
panels) and norepinephrine (right panels) with coronary vascular
resistance (CVR). A, Alpha- and beta-blockade in protocol 1A (seven
dogs). B, Beta-blockade in protocol 1B (seven dogs). C, Alpha- and
beta-blockade plus BIBP3226 in protocol 1C (seven dogs). Crosses 5
baseline values; triangles 5 2-Hz stimulation; diamonds 5 20-Hz
stimulation. L 5 liter.
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norepinephrine during ansae subclaviae stimulation (protocols
1 and 2). It has been reported that substances that act on KATP
channels may modify vessel reactivity to norepinephrine (16)
and to adenosine (14). In this study, we demonstrated a new
observation that KATP channel activity modifies the effects of
NPY (and norepinephrine) on vascular tone. As shown in
Figure 4 (protocol 4B), the effects of NPY were more markedly
(;100-fold) suppressed by KATP channel agonists than were
those of norepinephrine, indicating that the proportion of
KATP channel dependency in the vasoconstrictive action of
NPY is greater than that of norepinephrine. This observation
suggests that NPY-induced vasoconstriction would become
more marked than that of norepinephrine under the KATP
channel blockade of coronary vessels. Modification of CVR by
the KATP channel was more marked in the subepicardial than
in the subendocardial region during ansae subclaviae stimula-
tion (Table 1). These results indicate that there is transmural
heterogeneity in the mechanism regulating CVR by way of
KATP channels, as discussed previously (16).
Possible modulation of coronary vasoconstriction by other
transmitters during nerve stimulation. As well as K channels,
some other neurotransmitters should be considered as addi-
tional modulatory factors for CVR during electrical nerve
stimulation. ATP is coreleased from the sympathetic nerve
(4,25) and is immediately degraded into adenosine. Adenosine
is also produced in myocardium by ischemia (26). Calcitonin
gene-related peptide is released from the sensory nerve by
antidromic nerve stimulation (27). ATP caused vasoconstric-
tion (28), whereas adenosine (29,30) and calcitonin gene–
related peptide (31,32) caused vasodilation. Thus, these three
substances possibly modulate CVR during electrical nerve
stimulation. However, we have already reported that elec-
trical stimulation of the ventrolateral cardiac nerve increased
Figure 2. Dose-response curves of percent changes in coronary vas-
cular resistance (%CVR) with intracoronary administration of exoge-
nous neuropeptide Y and norepinephrine in protocol 3. Neuropeptide
Y (triangles) and norepinephrine (circles) were administered to
the coronary artery under alpha- and beta-blockade (A) and under
beta-blockade (B). Symbols and bars represent mean values and SD,
respectively, for the number of dogs indicated in parentheses.
ANCOVA was applied to examine the differences in the dose-response
curves (p , 0.001, neuropeptide Y vs. norepinephrine). *p , 0.05
versus baseline value (ANOVA).
Figure 3. Effect of adenosine triphosphate–sensitive potassium (KATP)
channel acting substances on the dose responsiveness of percent
changes in coronary vascular resistance (%CVR) induced by intra-
coronary administration of neuropeptide Y under beta-blockade in
protocol 4A. A, Effect of KATP channel antagonist glibenclamide
(triangles) in four dogs. B, Effect of KATP channel agonist (triangles)
pinacidil (three dogs) or nicorandil (three dogs). Control experiments
(circles) were done in the same dogs (data from protocol 3B). Symbols
and bars represent mean value and SD, respectively. ANCOVA was
applied to examine the differences in the dose-response curves: A, p ,
0.001, glibenclamide versus control; B, p , 0.001, KATP versus control.
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CVR in a frequency-dependent manner, where neither
8-phenyltheophylline (adenosine antagonist) nor calcitonin
gene–related peptide 8-37 (calcitonin gene–related peptide
antagonist) modified CVR change compared with the control
series (16). In the preliminary experiments, we confirmed that
intracoronary administration of alpha, beta-methylene ATP
(ATP antagonist [1.0 mg/kg per min]) had no effect on CVR
change during the ventrolateral cardiac nerve stimulation.
Other factors such as prostacyclin, endothelium-derived relax-
ing factor, endothelium-derived hyperpolarizing factor, endo-
thelin and others might be involved in the regulating mecha-
nisms. Sympathetic nerve stimulation augmented the release of
prostacyclin but did not affect the release of endothelium-
derived relaxing factor or endothelin in rabbit Langendorff
hearts (33). Inhibition of prostaglandin biosynthesis by keto-
profen or aspirin caused a paradoxic increase in CVR by cold
pressor test in humans (34). Inhibition of nitric oxide produc-
tion by Nv-nitro-L-arginine–enhanced nerve stimulation in-
duced norepinephrine release in rat Langendorff hearts (35)
but had no effect on CVR change during the ventrolateral
cardiac nerve stimulation in dogs in vivo (16). Little is known
concerning modulation of sympathetic coronary vasoconstric-
tion by endothelium-derived hyperpolarizing factor, endothe-
lin or other substances.
Consideration of the experimental model. To avoid meta-
bolic regulatory mechanisms, we stimulated sympathetic
nerves locally and used beta-blockade. In protocol 3, CVR
increased with negligible changes in heart rate and aortic
pressure, exhibiting almost complete independence of meta-
bolic regulation. In protocol 1, the ansae subclaviae stimula-
tion caused systemic hemodynamic changes even under beta-
blockade, and metabolic vasodilation consequently occurred.
However, beta-blockade at least minimized the increases in
heart rate (11%) and aortic pressure (13%, Table 1) exhibited
during sympathetic stimulation.
Alpha-blockade with phenoxybenzamine masked the effects
of the exogenous norepinephrine in protocol 3A and compet-
itively suppressed the effect of phenylephrine on vasoconstric-
tion as described in Methods (the threshold of phenylephrine
increased .30-fold), but it did not completely suppress the
augmentation of aortic pressure during ansae subclaviae stim-
ulation in protocol 1A. In other words, a few functioning
alpha-adrenoceptors are likely to have been present around
the synapse area. However, a lack of correlation between
norepinephrine and CVR under alpha-blockade indicates
that the blockade was sufficient for the present conclusions
related to NPY. NPY blockade with BIBP3226 enhanced
the increase in heart rate and neurotransmitter overflows at
20 Hz. These changes were probably due to suppression of
presynaptic inhibition of transmitter release by way of the
NPY receptor.
We thank Klaus Rudolf, PhD of Dr. Karl Thomae GmbH for the generous
supply of BIBP3226, Yoshiko Shinozaki and Yoko Takahari for technical
assistance, and Kevin Boru, PhD for editing the manuscript.
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